frontotemporal pain associated with migraine
Conditions
Interventions
Control Group:Standard pharmacological therapy with oral flunarizine
PRF Group:Percutaneous pulsed radiofrequency (PRF) treatment targeting the C2 nerve root
RFT Group:Percutaneous conventional radiofrequency thermocoagulation (RFT) of the C2 nerve root
Sponsors
Xuanwu Hospital Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Diagnosis of migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3, 2018) criteria; 2. Age >=18 years, either sex; 3. Pain intensity >=4 on a 0-10 Visual Analog Scale (VAS); 4. ASA physical status I or II (American Society of Anesthesiologists classification); 5. Brain MRI demonstrating no secondary causes for headache; 6. Provision of signed informed consent prior to study participation.
Exclusion criteria
Exclusion criteria: 1. Significant cardiovascular or cerebrovascular disease; ASA physical status III or higher; 2. Coagulopathy or bleeding diathesis; contraindication to anticoagulation or current use of anticoagulants with unacceptable bleeding risk; 3. Active or suspected systemic/local infection (clinical signs and/or laboratory evidence) requiring antimicrobial treatment prior to intervention; 4. Pregnancy, lactation, or planning pregnancy (women of childbearing potential must have negative serum/urine pregnancy test and agree to use effective contraception); 5. History of hypersensitivity or allergic reaction to flunarizine, triptans, or lidocaine/local anesthetics.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in headache attack frequency at 6 months post-intervention; | — |
Secondary
| Measure | Time frame |
|---|---|
| Migraine Disability Assessment Scale;Monthly frequency of acute medication (triptan) use;Pituitary Adenylate Cyclase Activating Polypeptide, PACAP;Pain Visual Analogue Scale;Headache Impact Test-6;Calcitonin Gene-Related Peptide, CGRP ;Duration of headache attacks;Migraine-Specific Quality of Life Questionnaire version 2.1; | — |
Countries
China
Contacts
Public ContactLiqiang Yang
Xuanwu Hospital Capital Medical University
Outcome results
None listed